Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings results on Thursday. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03, FiscalAI reports. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Xeris reported third-quarter revenue of $107.2 million, up 44% year over year, and raised 2026 revenue guidance to $395 million–$405 million. Management also raised its 2030 revenue outlook from $750 million to more than $1 billion.
• Recorlev revenue nearly doubled year over year to $71.5 million, with record referrals and patient starts following the expanded commercial team’s ramp-up. Management expects momentum to continue, supported by broader screening for hypercortisolism, though access still typically requires prior authorization.
• Gvoke prescriptions rose 5% year over year, but net revenue fell to $21.7 million from $25.2 million a year earlier because of a one-time $4 million Medicaid gross-to-net adjustment. Management said demand improved through the quarter and expects the brand to return to growth.
• KEVEYIS generated $13 million in revenue, its fourth consecutive quarter of year-over-year growth, and received a U.S. patent extending protection through at least 2043. The company plans additional investment to find and support more patients.
• Xeris remains on track to start the pivotal Phase III Cornerstone study of XP-8121 by year-end, with topline results expected in late 2028 and a potential 2030 launch. Management cited peak sales potential of $1 billion–$3 billion, although the opportunity depends on successful clinical development.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $15.20 on Friday. The firm has a market capitalization of $2.77 billion, a price-to-earnings ratio of -303.94 and a beta of 0.61. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma has a one year low of $5.25 and a one year high of $15.21. The business has a 50-day simple moving average of $9.62 and a 200 day simple moving average of $7.62.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Barclays boosted their price target on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. Leerink Partners raised their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. HC Wainwright raised their price target on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a research report on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.20.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total transaction of $312,250.00. Following the transaction, the insider directly owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the sale, the insider directly owned 1,346,053 shares in the company, valued at approximately $13,770,122.19. The trade was a 0.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.